phrykt

Gilead Sciences, Inc. (GILD): who owns it and who trades it

As of Nov 16, 2026, GILD insiders reported 82 open-market sales worth $105M and no purchases in the last 12 months, with 99% of the sale value made under pre-set 10b5-1 plans. The largest seller was Daniel Patrick O'Day (CEO), with $76.3M. 7 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Gilead Sciences

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns GILD

2,263 funds and institutions reported GILD shares worth $141B at the end of Q2 2026, about 90% of the company. The largest holder is BlackRock, Inc. with 9.8%.

Funds and institutions (13F) 90%Everyone else 10%

10 largest owners, by share of the company

BlackRock, Inc.9.8%
Vanguard Capital Management LLC6.5%
FMR LLC (Fidelity)5.4%
State Street Corp4.9%
Capital World Investors3.3%
Invesco Ltd.3.2%
Vanguard Portfolio Management LLC2.8%
Geode Capital Management, LLC2.4%
T. Rowe Price Associates2.4%
Morgan Stanley1.9%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.121.84M9.81%$15.4B+2%
Vanguard Capital Management LLC81.09M6.53%$10.2B+1%
FMR LLC (Fidelity)66.87M5.39%$8.4B-7%
State Street Corp61.22M4.93%$7.7B+2%
Capital World Investors40.99M3.30%$5.2B-1%
Invesco Ltd.39.82M3.21%$5B+156%
Vanguard Portfolio Management LLC35.32M2.84%$4.5B+1%
Geode Capital Management, LLC30.07M2.42%$3.8B+1%
T. Rowe Price Associates30.00M2.42%$3.8B+14%
Morgan Stanley24.00M1.93%$3B+3%
Dodge & Cox23.68M1.91%$3B-2%
Norges Bank21.97M1.77%$2.8B–
JPMorgan Chase & Co20.82M1.68%$2.6B–
Capital Research Global Investors19.39M1.56%$2.5B-29%
Bank of America Corp18.65M1.50%$2.4B-7%
Bank of New York Mellon Corp15.26M1.23%$1.9B+1%
Northern Trust Corp13.83M1.11%$1.7B+0%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC12.99M1.05%$1.6B-2%
Wellington Management Group LLP12.70M1.02%$1.6B-6%
Goldman Sachs Group Inc10.78M0.87%$1.4B-3%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, GILD insiders reported $0 of open-market purchases and $105M of sales. 99% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$105M
82 trades, 7 people
Sales under a 10b5-1 plan
99%
Share of sale value
Latest trade
Nov 12, 2026
Filed Nov 16, 2026

Purchases and sales by month

$24.6M$24.6MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 12, 2026Kelly A. KramerDirectorSale plan1,676$168.23$282KForm 4
Nov 12, 2026Kelly A. KramerDirectorSale plan3,800$169.44$644KForm 4
Nov 12, 2026Kelly A. KramerDirectorSale plan4,700$170.49$801KForm 4
Nov 12, 2026Kelly A. KramerDirectorSale plan200$171.44$34.3KForm 4
Nov 6, 2026Wettan Keeley M CainVice presidentSale plan3,399$164.11$558KForm 4
Nov 5, 2026Daniel Patrick O'DayCEOSale plan9,810$175.17$1.7MForm 4
Nov 4, 2026Daniel Patrick O'DayCEOSale plan102,619$175.16$18MForm 4
Nov 2, 2026Daniel Patrick O'DayCEOSale plan1,600$167.40$268KForm 4
Nov 2, 2026Daniel Patrick O'DayCEOSale plan1,700$168.10$286KForm 4
Nov 2, 2026Daniel Patrick O'DayCEOSale plan1,904$169.27$322KForm 4
Nov 2, 2026Daniel Patrick O'DayCEOSale plan7,796$170.35$1.3MForm 4
Nov 2, 2026Daniel Patrick O'DayCEOSale plan2,000$171.06$342KForm 4
Oct 30, 2026Daniel Patrick O'DayCEOSale plan15,881$175.25$2.8MForm 4
Oct 15, 2026Andrew D DickinsonCFOSale plan3,000$156.22$469KForm 4
Oct 1, 2026Daniel Patrick O'DayCEOSale plan12,000$147.72$1.8MForm 4
Oct 1, 2026Daniel Patrick O'DayCEOSale plan3,000$148.63$446KForm 4
Sep 15, 2026Andrew D DickinsonCFOSale plan3,000$145.29$436KForm 4
Sep 15, 2026Johanna MercierChief Comm & Corp Aff OfSale plan1,600$143.69$230KForm 4
Sep 15, 2026Johanna MercierChief Comm & Corp Aff OfSale plan800$144.46$116KForm 4
Sep 15, 2026Johanna MercierChief Comm & Corp Aff OfSale plan600$145.29$87.2KForm 4
Sep 1, 2026Daniel Patrick O'DayCEOSale plan1,600$147.51$236KForm 4
Sep 1, 2026Daniel Patrick O'DayCEOSale plan7,992$148.36$1.2MForm 4
Sep 1, 2026Daniel Patrick O'DayCEOSale plan5,408$149.38$808KForm 4
Aug 26, 2026Anthony WeltersDirectorSale plan4,600$148.82$685KForm 4
Aug 26, 2026Anthony WeltersDirectorSale plan6,880$148.82$1MForm 4
Aug 26, 2026Anthony WeltersDirectorSale plan3,402$148.24$504KForm 4
Aug 26, 2026Anthony WeltersDirectorSale plan3,118$148.31$462KForm 4
Aug 20, 2026Jeffrey BluestoneDirectorSale plan1,658$145.73$242KForm 4
Aug 20, 2026Jeffrey BluestoneDirectorSale plan1,816$144.92$263KForm 4
Aug 20, 2026Jeffrey BluestoneDirectorSale plan1,165$143.75$167KForm 4
Aug 20, 2026Jeffrey BluestoneDirectorSale plan335$146.26$49KForm 4
Aug 20, 2026Jeffrey BluestoneDirectorSale plan26$146.36$3.8KForm 4
Aug 17, 2026Andrew D DickinsonCFOSale plan3,000$138.36$415KForm 4
Aug 17, 2026Johanna MercierChief Comm & Corp Aff OfSale plan11,470$138.04$1.6MForm 4
Aug 17, 2026Johanna MercierChief Comm & Corp Aff OfSale plan16,530$137.37$2.3MForm 4
Aug 3, 2026Daniel Patrick O'DayCEOSale plan6,700$129.66$869KForm 4
Aug 3, 2026Daniel Patrick O'DayCEOSale plan600$131.34$78.8KForm 4
Aug 3, 2026Daniel Patrick O'DayCEOSale plan7,700$130.80$1MForm 4
Jul 15, 2026Andrew D DickinsonCFOSale plan3,000$129.93$390KForm 4
Jul 15, 2026Johanna MercierChief Comm & Corp Aff OfSale plan3,000$129.92$390KForm 4
Jul 1, 2026Daniel Patrick O'DayCEOSale plan11,900$126.09$1.5MForm 4
Jul 1, 2026Daniel Patrick O'DayCEOSale plan3,100$127.08$394KForm 4
Jun 15, 2026Johanna MercierChief Comm & Corp Aff OfSale plan1,480$123.42$183KForm 4
Jun 15, 2026Johanna MercierChief Comm & Corp Aff OfSale plan450$125.40$56.4KForm 4
Jun 15, 2026Johanna MercierChief Comm & Corp Aff OfSale plan1,070$124.00$133KForm 4
Jun 15, 2026Andrew D DickinsonCFOSale plan3,000$125.40$376KForm 4
Jun 1, 2026Daniel Patrick O'DayCEOSale plan10,900$131.10$1.4MForm 4
Jun 1, 2026Daniel Patrick O'DayCEOSale plan3,062$132.22$405KForm 4
Jun 1, 2026Daniel Patrick O'DayCEOSale plan1,038$132.97$138KForm 4
May 15, 2026Andrew D DickinsonCFOSale plan3,000$132.27$397KForm 4
May 15, 2026Johanna MercierChief Comm & Corp Aff OfSale plan700$132.75$92.9KForm 4
May 15, 2026Johanna MercierChief Comm & Corp Aff OfSale plan11,177$131.19$1.5MForm 4
May 15, 2026Johanna MercierChief Comm & Corp Aff OfSale plan8,374$132.23$1.1MForm 4
May 15, 2026Johanna MercierChief Comm & Corp Aff OfSale plan7,749$130.29$1MForm 4
Apr 28, 2026Daniel Patrick O'DayCEOSale plan3,050$130.01$397KForm 4
Apr 28, 2026Daniel Patrick O'DayCEOSale plan6,950$128.79$895KForm 4
Apr 15, 2026Andrew D DickinsonCFOSale plan3,000$140.96$423KForm 4
Mar 27, 2026Daniel Patrick O'DayCEOSale plan10,000$136.82$1.4MForm 4
Mar 16, 2026Johanna MercierChief Comm & Corp Aff OfSale plan3,000$144.23$433KForm 4
Feb 27, 2026Daniel Patrick O'DayCEOSale plan3,481$144.04$501KForm 4
Feb 27, 2026Daniel Patrick O'DayCEOSale plan6,419$145.18$932KForm 4
Feb 27, 2026Daniel Patrick O'DayCEOSale plan100$145.71$14.6KForm 4
Feb 17, 2026Johanna MercierChief Comm & Corp Aff OfSale plan18,405$154.18$2.8MForm 4
Feb 17, 2026Johanna MercierChief Comm & Corp Aff OfSale plan9,395$154.91$1.5MForm 4
Feb 17, 2026Johanna MercierChief Comm & Corp Aff OfSale plan200$155.62$31.1KForm 4
Feb 17, 2026Andrew D DickinsonCFOSale plan3,000$154.43$463KForm 4
Feb 5, 2026Daniel Patrick O'DayCEOSale plan115,640$150.00$17.3MForm 4
Jan 28, 2026Daniel Patrick O'DayCEOSale plan4,968$140.24$697KForm 4
Jan 28, 2026Daniel Patrick O'DayCEOSale plan5,032$139.54$702KForm 4
Jan 23, 2026Daniel Patrick O'DayCEOSale plan115,640$135.00$15.6MForm 4
Jan 20, 2026Jeffrey BluestoneDirectorSale plan5,000$123.50$618KForm 4
Jan 15, 2026Andrew D DickinsonCFOSale plan3,000$124.31$373KForm 4
Dec 29, 2025Daniel Patrick O'DayCEOSale plan10,000$124.83$1.2MForm 4
Dec 15, 2025Andrew D DickinsonCFOSale plan3,000$122.00$366KForm 4
Nov 28, 2025Jeffrey BluestoneDirectorSale5,000$125.08$625KForm 4
Nov 28, 2025Kelly A. KramerDirectorSale plan2,805$127.10$357KForm 4
Nov 28, 2025Daniel Patrick O'DayCEOSale plan6,788$126.84$861KForm 4
Nov 28, 2025Daniel Patrick O'DayCEOSale plan3,212$125.91$404KForm 4
Nov 26, 2025Kelly A. KramerDirectorSale plan2,806$127.11$357KForm 4
Nov 17, 2025Andrew D DickinsonCFOSale plan2,500$125.23$313KForm 4
Nov 17, 2025Johanna MercierChief Commercial OfficerSale plan2,476$126.26$313KForm 4
Nov 17, 2025Johanna MercierChief Commercial OfficerSale plan25,524$125.83$3.2MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Daniel Patrick O'DayChairman & CEO, Director–$76.3MNov 5, 2026
Johanna MercierChief Commercial Officer–$17MSep 15, 2026
Andrew D DickinsonChief Financial Officer–$4.4MOct 15, 2026
Anthony WeltersDirector–$2.7MAug 26, 2026
Kelly A. KramerDirector–$2.5MNov 12, 2026
Jeffrey BluestoneDirector–$2MAug 20, 2026
Wettan Keeley M CainEVP Gen Counsel, Legal & Comp–$558KNov 6, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

GILD short interest

Low short interest. 1.7% of GILD shares are sold short: about 1 share in 58. Over the last 12 reports the number of shares short went down 8%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 21.27M GILD shares were sold short, 1.7% of the shares outstanding, up 4.9% from the report before. At the average daily volume of 6.70M shares, buying them all back would take about 3.2 trading days (days to cover).

Shares short, % of all shares

1.72%May 15Oct 302.16%

Days to cover

3.2May 15Oct 304.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202621.27M1.72%+5%6.70M3.2
Oct 15, 202620.27M1.63%-7%5.45M3.7
Sep 30, 202621.83M1.76%+19%6.50M3.4
Sep 15, 202618.30M1.48%-20%5.02M3.6
Aug 31, 202623.01M1.86%-1%5.44M4.2
Aug 14, 202623.18M1.87%-5%7.15M3.2
Jul 31, 202624.39M1.97%-3%6.31M3.9
Jul 15, 202625.26M2.03%-1%6.89M3.7
Jun 30, 202625.48M2.05%+7%9.60M2.7
Jun 15, 202623.86M1.92%-7%8.87M2.7
May 29, 202625.73M2.07%+11%6.74M3.8
May 15, 202623.14M1.86%+0%6.50M3.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded GILD

Since Nov 17, 2024, 8 members of Congress reported 9 purchases and 4 sales of GILD. The latest was a purchase by Jared Moskowitz on May 6, 2026, reported Jun 19, 2026.

Purchases 9Sales 4

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
May 6, 2026Jared Moskowitz (D-FL)Purchase$1K–$15KChildJun 19, 2026Report
May 6, 2026Jared Moskowitz (D-FL)Purchase$1K–$15KSelfJun 19, 2026Report
Mar 27, 2026Alan Armstrong (R-OK)Purchase$1K–$15KSelfJul 21, 2026Report
Jan 27, 2026Josh Gottheimer (D-NJ)Purchase$1K–$15KJointFeb 26, 2026Report
Sep 23, 2025Val T. Hoyle (D-OR)Sale$1K–$15KSpouseOct 10, 2025Report
Jun 6, 2025Marjorie Greene (GA)Purchase$1K–$15KSelfJun 18, 2025Report
May 14, 2025Josh Gottheimer (D-NJ)Sale$1K–$15KJointJun 11, 2025Report
May 12, 2025Jefferson Shreve (R-IN)Sale$15K–$50KSelfJun 22, 2025Report
May 5, 2025Marjorie Greene (GA)Purchase$1K–$15KSelfMay 6, 2025Report
Apr 16, 2025John Boozman (R-AR)Sale$1K–$15KJointMay 14, 2025Report
Mar 31, 2025Jefferson Shreve (R-IN)Purchase$15K–$50KSelfApr 11, 2025Report
Mar 10, 2025Carol D. Miller (R-WV)Purchase$1K–$15KSelfApr 11, 2025Report
Mar 7, 2025Josh Gottheimer (D-NJ)Purchase$1K–$15KJointApr 10, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Gilead Sciences company events

Gilead Sciences filed 9 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Oct 29, 2026.

  1. Oct 29, 2026ResultsReleased financial results. Filing
  2. Aug 4, 2026ResultsReleased financial results. Filing
  3. May 20, 2026AgreementGilead Sciences, Inc. and Computershare Trust Company, National Association, as successor to Wells Fargo Bank, National Association, as trustee, entered into an Eleventh Supplemental Indenture to the Indenture between the Parties, dated as of March 30, 2011. Filing
  4. May 7, 2026ResultsReleased financial results. Filing
  5. May 4, 2026VoteReported shareholder vote results. Filing
  6. Apr 28, 2026AnnouncementAs previously disclosed, on February 22, 2026, Gilead entered into an Agreement and Plan of Merger, among Parent, the Company and Ravens Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent. Filing
  7. Feb 23, 2026AgreementGilead Sciences, Inc., a Delaware corporation, entered into an Agreement and Plan of Merger, among Parent, Arcellx, Inc., a Delaware corporation, and Ravens Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent. Filing
  8. Feb 10, 2026ResultsReleased financial results. Filing
  9. Nov 19, 2025LeadershipOn November 19, 2025, Gilead Sciences, Inc., a Delaware corporation, announced that Deborah H. Telman will no longer serve as Executive Vice President, Corporate Affairs and General Counsel of the Company as of December 5, 2025. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

How Gilead Sciences makes money

Biktarvy (HIV) brought in half of Gilead Sciences's revenue ($14.3B of $29.4B) in 2025. Cell therapy was next, at 6%.

By product or service, 2025

Biktarvy (HIV)$14.3B · 49%
Cell therapy$1.8B · 6%
Genvoya (HIV)$1.5B · 5%
Yescarta$1.5B · 5%
Trodelvy$1.4B · 5%
Epclusa (liver disease)$1.3B · 4%
Odefsey (HIV)$1.2B · 4%
Vemlidy (liver disease)$1.1B · 4%
Veklury$911M · 3%
Liver Disease Products, Other Liver Disease$874M · 3%
Other Products, Total Other product sales$799M · 3%
Royalty, Contract, And Other$527M · 2%

By region, 2025

United States$20.9B · 71%
Europe$5.1B · 17%
Rest Of World$3.5B · 12%

From Gilead Sciences's annual report (10-K) for the year ended Dec 31, 2025, filed Feb 24, 2026. The company chooses how to group its revenue, so the parts differ from one company to the next. Read the filing · How the biggest companies make money

Gilead Sciences financials

Famous investors that hold GILD

7 of the 50 well-known investors we track reported holding GILD in their latest 13F filing. The largest position is Jim Simons's, worth $306M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20262.05M$306M0.4%-7%
Ken Griffin · Citadel AdvisorsQ3 20261.73M$258M0.1%-50%
Israel Englander · Millennium ManagementQ3 20261.63M$243M0.2%+12%
Paul Tudor Jones · Tudor Investment CorpQ3 2026564,443$84.1M0.4%+654%
Ray Dalio · Bridgewater AssociatesQ3 2026321,419$47.9M0.2%+10%
Ken Fisher · Fisher Asset ManagementQ3 2026305,850$45.6M0.0%+1516%
Lee Ainslie · Maverick CapitalQ3 20263,256$485K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Gilead Sciences, Inc. (GILD) stock

Who owns the most GILD stock?

The largest reported owner of Gilead Sciences, Inc. (GILD) is BlackRock, Inc., with 9.8% of the company. In total, 2,263 funds and institutions reported holding GILD at the end of Q2 2026, together about 90% of the shares. See the largest owners.

Are GILD insiders buying or selling?

In the last 12 months, GILD insiders reported no open-market purchases and 82 sales worth $105M. The latest trade was on Nov 12, 2026. See every trade.

What is the short interest in GILD?

As of Oct 30, 2026, 21.27M GILD shares were sold short, 1.7% of the shares outstanding, up 4.9% from the report before. At the average daily volume of 6.70M shares, buying them all back would take about 3.2 trading days (days to cover). See the history.

Have members of Congress traded GILD?

Yes. 8 members of Congress reported 9 purchases and 4 sales of GILD since Nov 17, 2024. The latest was reported on Jul 21, 2026. See the trades.

How does Gilead Sciences make money?

Biktarvy (HIV) brought in half of Gilead Sciences's revenue ($14.3B of $29.4B) in 2025. Cell therapy was next, at 6%. See the full split.

Which famous investors hold GILD?

7 of the 50 well-known investors we track reported GILD in their latest 13F filing, including Jim Simons, Ken Griffin, Israel Englander. The largest position is worth $306M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.